{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 445783136
| IUPAC_name = (''RS'')-5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine
| image = Nefopam2DACS.svg
| width = 135px
| image2 = File:Nefopam ball-and-stick model.png
| width2 = 150px

<!--Clinical data-->
| tradename = Acupan
| Drugs.com = {{drugs.com|international|nefopam}}
| pregnancy_category = 
| legal_AU = S4
| legal_UK = POM
| routes_of_administration = [[Oral administration|Oral]], [[intramuscular injection|intramuscular]], [[intravenous therapy|intravenous]]

<!--Pharmacokinetic data-->
| bioavailability = Low<ref name="pmid26796604">{{cite journal | vauthors = Sanga M, Banach J, Ledvina A, Modi NB, Mittur A | title = Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers | journal = Xenobiotica | volume = 46 | issue = 11 | pages = 1001–16 | year = 2016 | pmid = 26796604 | doi = 10.3109/00498254.2015.1136989 | url = }}</ref>
| protein_bound = 70–75% (mean 73%)<ref name="pmid26796604" /><ref name="Seyffart2012">{{cite book|author=G. Seyffart|title=Drug Dosage in Renal Insufficiency|url=https://books.google.com/books?id=OavnCAAAQBAJ&pg=PA407|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-3804-8|pages=407–}}</ref>
| metabolism = [[Liver]] (''N''-[[demethylation]], others)<ref name="pmid26796604" />
| metabolites = Desmethylnefopam, others<ref name="pmid26796604" />
| elimination_half-life = Nefopam: 3–8 hours<ref name="pmid26796604" /><br />Desmethylnefopam: 10–15 hours<ref name="pmid26796604" />
| excretion = [[Urine]]: 79.3%<ref name="pmid26796604" /><br />[[Feces]]: 13.4%<ref name="pmid26796604" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 13669-70-0
| ATC_prefix = N02
| ATC_suffix = BG06
| PubChem = 4450
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4UP8060B7J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08258
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 88316
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4295
| synonyms = 

<!--Chemical data-->
| C=17 | H=19 | N=1 | O=1 
| molecular_weight = 253.34 g/mol
| SMILES = CN1CCOC(C2=CC=CC=C2C1)C3=CC=CC=C3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RGPDEAGGEXEMMM-UHFFFAOYSA-N
}}

'''Nefopam''', sold under the brand names '''Acupan''' among others, is a [[analgesic|painkilling medication]]. It is primarily used to treat moderate, [[acute (medicine)|acute]] or [[chronic pain]]. <ref name="MD">{{cite web|title=Nefopam hydrochloride|website=MedicinesComplete|publisher=Pharmaceutical Press|editor=Brayfield, A|url=https://www.medicinescomplete.com/mc/martindale/current/2674-m.htm|location=London, UK|date=27 October 2016|accessdate=4 September 2017}}</ref>

It is believed to work in the brain and spinal cord to relieve pain. There it is believed to work via rather unique mechanisms. Firstly it increases the activity of the [[serotonin]], [[norepinephrine]] and [[dopamine]], [[neurotransmitters]] involved in, among other things, pain signaling. Secondly, it modulates [[sodium channel|sodium]] and [[calcium channels]], thereby inhibiting the release of [[glutamate]], a key neurotransmitter involved in pain processing.<ref name="RevPharm2016"/>

==Medical uses==
Nefopam has additional action in the prevention of shivering, which may be a side effect of other drugs used in surgery.<ref name="Alfonsi">{{cite journal |vauthors=Alfonsi P, Adam F, Passard A, Guignard B, Sessler DI, Chauvin M | title= Nefopam, a Non-sedative Benzoxazocine Analgesic, Selectively Reduces the Shivering Threshold | journal=Anesthesiology |date=January 2004 | pages=37&ndash;43 | volume=100 | issue=1 | pmid=14695722 | doi= 10.1097/00000542-200401000-00010 | pmc= 1283107}}</ref> Nefopam was significantly more effective than [[aspirin]] as an analgesic in one clinical trial,<ref name="Cohen">{{cite journal |vauthors=Cohen A, Hernandez CM | title= Nefopam hydrochloride: new analgesic agent | journal= Journal of International Medical Research | year=1976 | pages=138&ndash;43 | volume=4 | issue=2 | pmid=799984}}</ref> although with a greater incidence of side effects such as sweating, dizziness and nausea, especially at higher doses.<ref name="Wang">{{cite journal |vauthors=Wang RI, Waite EM | title= The clinical analgesic efficacy of oral nefopam hydrochloride | journal= Journal of Clinical Pharmacology |date=July 1979 | pages= 395&ndash;402 | volume=19 | issue=7 | pmid=479385 | doi=10.1002/j.1552-4604.1979.tb02498.x}}</ref><ref name="Pillians">{{cite journal |vauthors=Pillans PI, Woods DJ | title= Adverse reactions associated with nefopam | journal= New Zealand Medical Journal |date=September 1995 | pages= 382&ndash;4 | volume= 108 | issue= 1008 | pmid=7566787}}</ref> Nefopam is around a third to half the potency and slightly less effective as an analgesic compared to [[morphine]],<ref name="Sunshine">{{cite journal |vauthors=Sunshine A, Laska E | title= Nefopam and morphine in man | journal= Clinical Pharmacology and Therapeutics |date=November 1975 | pages= 530&ndash;4 | volume= 18 | issue= 5 Pt 1 | pmid=1102231}}</ref><ref name="Phillips">{{cite journal |vauthors=Phillips G, Vickers MD | title= Nefopam in postoperative pain | journal= British Journal of Anaesthesia |date=October 1979 | pages= 961&ndash;5 | volume=51 | issue=10 | pmid=391253 | doi= 10.1093/bja/51.10.961}}</ref><ref name="Heel">{{cite journal |vauthors=Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS | title= Nefopam: a review of its pharmacological properties and therapeutic efficacy
| journal= Drugs | year=1980 | pages= 249&ndash;67 | volume= 19 | issue=4 | pmid=6991238 | doi= 10.2165/00003495-198019040-00001}}</ref> or [[oxycodone]],<ref name="Tigerstedt">{{cite journal |vauthors=Tigerstedt I, Tammisto T, Leander P | title=Comparison of the analgesic dose-effect relationships of nefopam and oxycodone in postoperative pain | journal= Acta Anaesthesiologica Scandinavica |date=December 1979 | pages= 555&ndash;60 | volume=23 | issue= 6 | pmid=397711 | doi= 10.1111/j.1399-6576.1979.tb01486.x}}</ref> but tends to produce fewer side effects, does not produce respiratory depression,<ref name="Gasser">{{cite journal |vauthors=Gasser JC, Bellville JW | title= Respiratory effects of nefopam | journal= Clinical Pharmacology and Therapeutics |date=August 1975 | pages=175&ndash;9 | volume=18 | issue=2 | pmid=1097153}}</ref> and has much less [[drug abuse|abuse]] potential, and so is useful either as an alternative to opioids, or as an adjunctive treatment for use alongside opioid(s) or other analgesics.<ref name="Heel"/><ref name="Kapfer">{{cite journal |vauthors=Kapfer B, Alfonsi P, Guignard B, Sessler DI, Chauvin M | title= Nefopam and Ketamine Comparably Enhance Postoperative Analgesia | journal= Anesthesia and Analgesia |date=January 2005 | pages= 169&ndash;74 | volume=100 | issue=1 | pmid=15616073 | doi= 10.1213/01.ANE.0000138037.19757.ED | pmc= 1283103}}</ref> Nefopam is also used to treat severe [[hiccups]].<ref>{{cite journal|last=Bilotta|first=F|author2=Rosa, G|title=Nefopam for severe hiccups.|journal=The New England Journal of Medicine|date=December 2000|volume=343|issue=26|pages=1973–4|pmid=11186682|doi=10.1056/nejm200012283432619}}</ref>

==Contraindications==
Nefopam is contraindicated in people with convulsive disorders, those that have received treatment with irreversible [[monoamine oxidase inhibitors]] such as [[phenelzine]], [[tranylcypromine]] or [[isocarboxazid]] within the past 30 days and those with [[myocardial infarction]] pain, mostly due to a lack of safety data in these conditions.<ref name = MS/>

==Side effects==
Common side effects include nausea, nervousness, dry mouth, light-headedness and [[urinary retention]].<ref name = MS>{{cite web|title=Data Sheet ACUPAN™ Nefopam hydrochloride 30 mg tablets 20 mg intramuscular injection|work=Medsafe New Zealand|publisher=iNova Pharmaceuticals (New Zealand) Limited|date=3 September 2007|url=http://www.medsafe.govt.nz/profs/datasheet/a/acupantabinj.pdf|format=PDF|accessdate=10 March 2014}}</ref> Less common side effects include vomiting, blurred vision, drowsiness, sweating, insomnia, headache, confusion, hallucinations, tachycardia, aggravation of angina and rarely a temporary and benign pink discolouration of the skin or [[erythema multiforme]].<ref name = MS/>

==Overdose==
[[Overdose]] and death have been reported with nefopam,<ref name="pmid3448182">{{cite journal|last=Bismuth|first=C|author2=Fournier, PE |author3=Bavoux, E |author4=Husson, O |author5= Lafon, D |title=[Chronic abuse of the analgesic nefopam (Acupan)].|journal=Journal de Toxicologie Clinique et Experimentale|date=September 1987|volume=7|issue=5|pages=343–6|pmid=3448182|language=French}}</ref> although these events are less common with nefopam than with opioid analgesics.<ref name="pmid12054367">{{cite journal|last=Tracqui|first=A|author2=Berthelon, L |author3=Ludes, B |title=Fatal overdosage with nefopam (Acupan).|journal=Journal of Analytical Toxicology|date=May 2002|volume=26|issue=4|pages=239–43|doi=10.1093/jat/26.4.239|pmid=12054367|format=PDF|url=http://jat.oxfordjournals.org/content/26/4/239.full.pdf}}</ref> Overdose usually manifests with [[convulsion]]s, [[hallucination]]s, [[tachycardia]], and [[hyperdynamic circulation]].<ref name = MS/> Treatment is usually supportive, managing cardiovascular complications with [[beta blockers]] and limiting absorption with [[activated charcoal]].<ref name = MS/>

==Interactions==
It has additive anticholinergic and sympathomimetic effects with other agents with these properties.<ref name = MS/> Its use should be avoided in people receiving some types of antidepressants ([[tricyclic antidepressants]] or [[monoamine oxidase inhibitors]]) as there is the potential for [[serotonin syndrome]] or [[hypertensive crises]] to result.<ref name = MS/>

==Pharmacology==
{| class="wikitable floatleft sortable"
|+ Nefopam<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=nefopam&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref><ref name="pmid22711801">{{cite journal|last=Gregori-Puigjané|first=E.|author2=Setola, V |author3=Hert, J |author4=Crews, BA |author5=Irwin, JJ |author6=Lounkine, E |author7=Marnett, L |author8=Roth, BL |author9= Shoichet, BK |title=Identifying mechanism-of-action targets for drugs and probes|journal=Proceedings of the National Academy of Sciences|date=18 June 2012|volume=109|issue=28|pages=11178–11183|doi=10.1073/pnas.1204524109|pmid=22711801|url=http://www.pnas.org/content/early/2012/06/12/1204524109.full.pdf|format=PDF |pmc=3396511}}</ref>
! Site || K<sub>i</sub> (nM)
|-
| {{abbrlink|SERT|Serotonin transporter}} || 29
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 33
|-
| {{abbrlink|DAT|Dopamine transporter}} || 531
|-
| [[5-HT2A|5-HT<sub>2A</sub>]] || 1,685
|-
| [[5-HT2B|5-HT<sub>2B</sub>]] || 330
|-
| [[5-HT2C|5-HT<sub>2C</sub>]] || 56
|-
|}

The [[mechanism of action]] of nefopam and its [[analgesic]] effects are not well understood, although [[reuptake inhibitor|inhibition]] of the [[reuptake]] of [[serotonin]], [[norepinephrine]], and to a lesser extent [[dopamine]] (that is, acting as an {{abbrlink|SNDRI|serotonin–norepinephrine–dopamine reuptake inhibitor}}) is thought to be involved.<ref>{{cite web|author=Bausch & Lomb (NZ) Ltd|title=NEW ZEALAND DATA SHEET ACUPAN(TM)|url=http://www.medsafe.govt.nz/profs/Datasheet/a/acupantabinj.pdf|publisher=New Zealand The Ministry of Health|website=Medsafe|date=17 May 2017|accessdate=4 September 2017|format=PDF}}</ref><ref name="RevPharm2016"/> It also reduces [[glutamate]] signaling via modulating [[sodium channel|sodium]] and [[calcium channels]].<ref>{{cite journal|last1=Kim|first1=KH|last2=Abdi|first2=S|title=Rediscovery of nefopam for the treatment of neuropathic pain.|journal=The Korean Journal of Pain|date=April 2014|volume=27|issue=2|pages=103-11|doi=10.3344/kjp.2014.27.2.103|pmid=24748937|pmc=3990817}}</ref><ref name=RevPharm2016>{{cite journal|last1=Girard|first1=P|last2=Chauvin|first2=M|last3=Verleye|first3=M|title=Nefopam analgesia and its role in multimodal analgesia: A review of preclinical and clinical studies.|journal=Clinical and Experimental Pharmacology & Physiology|date=January 2016|volume=43|issue=1|pages=3-12|doi=10.1111/1440-1681.12506|pmid=26475417}}</ref>

==Pharmacokinetics==
The [[absolute bioavailability]] of nefopam is low.<ref name="pmid26796604" /> It is reported to achieve therapeutic plasma concentrations between 49 and 183&nbsp;nM.<ref name="pmid22711801" /> The drug is approximately 73% [[plasma protein binding|protein-bound]] across a plasma range of 7 to 226&nbsp;ng/mL (28–892&nbsp;nM).<ref name="pmid26796604" /> The [[metabolism]] of nefopam is [[hepatic]], by ''N''-[[demethylation]] and via other [[metabolic route|routes]].<ref name="pmid26796604" /> Its [[terminal half-life]] is 3 to 8 hours, while that of its [[active metabolite]], desmethylnefopam, is 10 to 15 hours.<ref name="pmid26796604" /> It is [[elimination (pharmacology)|eliminated]] mostly in [[urine]], and to a lesser extent in [[feces]].<ref name="pmid26796604" />

==Chemistry==
Nefopam is a [[cyclic compound|cyclized]] [[structural analogue|analogue]] of [[orphenadrine]], [[diphenhydramine]], and [[tofenacin]], with each of these compounds different from one another only by the presence of one or two [[carbon]]s.<ref name="WermuthAldous2015">{{cite book|author1=Camille Georges Wermuth|author2=David Aldous|author3=Pierre Raboisson|author4=Didier Rognan|title=The Practice of Medicinal Chemistry|url=https://books.google.com/books?id=dtScBAAAQBAJ&pg=PA250|date=1 July 2015|publisher=Elsevier Science|isbn=978-0-12-417213-5|pages=250–251}}</ref><ref name="Sneader2005">{{cite book|author=Walter Sneader|title=Drug Discovery: A History|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA405|date=23 June 2005|publisher=John Wiley & Sons|isbn=978-0-471-89979-2|pages=405–}}</ref><ref name="KubinyiMÃ1⁄4ller2006">{{cite book|author1=Hugo Kubinyi|author2=Gerhard MÃ1⁄4ller|title=Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective|url=https://books.google.com/books?id=oxvYXJSCImUC&pg=PA54|date=6 March 2006|publisher=John Wiley & Sons|isbn=978-3-527-60402-9|pages=54–}}</ref> The [[ring system (chemistry)|ring system]] of nefopam is a [[benzoxazocine]] system.<ref name="WermuthAldous2015" /><ref name="Cruz2014">{{cite book|author=Amy Cruz|title=Therapeutic Hypothermia|url=https://books.google.com/books?id=lpETxii5bjQC&pg=PA176|year=2014|publisher=CRC Press|pages=176–|id=GGKEY:R0AP2X4GZYF}}</ref>

==Society and culture==

===Recreational use===
Recreational use of nefopam has been reported,<ref name="pmid3448182" /> although this is less common than with opioid analgesics.<ref name="pmid12054367" />

==References==
{{Reflist|2}}

{{Analgesics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Ion channel modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}

[[Category:Analgesics]]
[[Category:Antidepressants]]
[[Category:Drugs with unknown mechanisms of action]]
[[Category:Muscarinic antagonists]]
[[Category:Nitrogen heterocycles]]
[[Category:Oxygen heterocycles]]
[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]
[[Category:Sodium channel blockers]]